A comparison of pediatric inflammatory multisystem syndrome temporarily-associated with SARS-CoV-2 and Kawasaki disease
- PMID: 36670127
- PMCID: PMC9857913
- DOI: 10.1038/s41598-022-26832-5
A comparison of pediatric inflammatory multisystem syndrome temporarily-associated with SARS-CoV-2 and Kawasaki disease
Abstract
The connection between Pediatric Inflammatory Multisystem Syndrome (PIMS) and Kawasaki Disease (KD) is not yet fully understood. Using the same national registry, clinical features and outcome of children hospitalized in Germany, and Innsbruck (Austria) were compared. Reported to the registry were 395 PIMS and 69 KD hospitalized patients. Patient age in PIMS cases was higher than in KD cases (median 7 [IQR 4-11] vs. 3 [IQR 1-4] years). A majority of both PIMS and KD patients were male and without comorbidities. PIMS patients more frequently presented with organ dysfunction, with the gastrointestinal (80%), cardiovascular (74%), and respiratory (52%) systems being most commonly affected. By contrast, KD patients more often displayed dermatological (99% vs. 68%) and mucosal changes (94% vs. 64%), plus cervical lymph node swelling (51% vs. 34%). Intensive care admission (48% vs. 19%), pulmonary support (32% vs. 10%), and use of inotropes/vasodilators (28% vs. 3%) were higher among PIMS cases. No patients died. Upon patient discharge, potentially irreversible sequelae-mainly cardiovascular-were reported (7% PIMS vs. 12% KD). Despite differences in age distribution and disease severity, PIMS and KD cases shared many common clinical and prognostic characteristics. This supports the hypothesis that the two entities represent a syndrome continuum.
© 2023. The Author(s).
Conflict of interest statement
Reinhard Berner received grants from the Federal State of Saxony, Germany. The study was partially supported by funding from the Federal State of Saxony, Germany. The Federal State of Saxony had no role in the design and conduct of the study. Jakob Armann received grants from the Federal State of Saxony, Germany. The study was partially supported by funding from the Federal State of Saxony, Germany. The Federal State of Saxony had no role in the design and conduct of the study. Jochen Schmitt received institutional funding for investigator-initiated research from Novartis, Sanofi, Pfizer, ALK, and acted as a consultant for Novartis, Sanofi, and Lilly in a function unrelated to this study. The other authors have no competing interests to disclose.
Figures


References
-
- World Health Organization (WHO). Multisystem inflammatory syndrome in children and adolescents with COVID-19. https://www.who.int/news-room/commentaries/detail/multisystem-inflammato... (2020). Accessed 10 July 2022.
Publication types
MeSH terms
Supplementary concepts
Associated data
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous